87
Views
6
CrossRef citations to date
0
Altmetric
Review

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?

&
Pages 163-172 | Published online: 22 May 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Megha Kothari, Prashant Mudireddy & Arun Swaminath. (2015) Patient considerations in the management of ulcerative colitis – role of vedolizumab. Therapeutics and Clinical Risk Management 11, pages 1235-1242.
Read now

Articles from other publishers (5)

Milan Buc. (2018) Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases. Vnitřní lékařství 64:3, pages 280-289.
Crossref
Bryant W Megna, Patrick R Carney & Gregory D Kennedy. (2016) Intestinal inflammation and the diet: Is food friend or foe?. World Journal of Gastrointestinal Surgery 8:2, pages 115.
Crossref
Wei-Qun Mei, Hui-Zhen Hu, Ying Liu, Zhi-Chen Li & Wei-Guo Wang. (2015) Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World Journal of Gastroenterology 21:19, pages 6044-6051.
Crossref
Wen-Song Ge & Jian-Gao Fan. (2015) Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis. World Journal of Gastroenterology 21:15, pages 4744-4749.
Crossref
Yang Gong, Lixing Liu, Xiaojuan He, Hongyan Zhao, Jing Yang, Li Li, Aiping Lu, Yifan Lin & Miao Jiang. (2015) The Th17/Treg Immune Balance in Ulcerative Colitis Patients with Two Different Chinese Syndromes: Dampness-Heat in Large Intestine and Spleen and Kidney Yang Deficiency Syndrome. Evidence-Based Complementary and Alternative Medicine 2015, pages 1-10.
Crossref